Drugs / Keluo Xin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03258242 | Aug 2017 → Aug 2019 | severe nonproliferative diabetic retinopathy | Chengdu Kanghong Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Keluo Xin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03258242 ↗ |
| Route | Oral | “taken orally” NCT03258242 ↗ |